Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Short-term Investments: 2012-2025

Historic Short-term Investments for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to $156.6 million.

  • Enanta Pharmaceuticals' Short-term Investments fell 25.78% to $156.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $156.6 million, marking a year-over-year decrease of 25.78%. This contributed to the annual value of $156.6 million for FY2025, which is 25.78% down from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Short-term Investments of $156.6 million as of Q3 2025, which was down 1.72% from $159.3 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year Short-term Investments high stood at $298.8 million for Q1 2021, and its period low was $132.3 million during Q4 2024.
  • Its 3-year average for Short-term Investments is $203.0 million, with a median of $194.3 million in 2024.
  • Over the last 5 years, Enanta Pharmaceuticals' Short-term Investments had its largest YoY gain of 72.94% in 2024, and its largest YoY loss of 55.47% in 2024.
  • Over the past 5 years, Enanta Pharmaceuticals' Short-term Investments (Quarterly) stood at $160.0 million in 2021, then grew by 7.67% to $172.2 million in 2022, then surged by 72.55% to $297.2 million in 2023, then tumbled by 55.47% to $132.3 million in 2024, then fell by 25.78% to $156.6 million in 2025.
  • Its Short-term Investments was $156.6 million in Q3 2025, compared to $159.3 million in Q2 2025 and $133.2 million in Q1 2025.